Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;27(2):507-10.
doi: 10.1038/leu.2012.209. Epub 2012 Jul 19.

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry

E Matutes, A G Bosanquet, R Wade, S M Richards, M Else, D Catovsky
Free PMC article

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry

E Matutes et al. Leukemia. 2013 Feb.
Free PMC article
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) OS from second randomization by TRAC-assay-guided (hashed line) vs protocol-guided arm (solid line). (b) OS by in vitro sensitivity to the given second-line treatment (sensitive=solid line, intermediate=hashed line, resistant=hashed/dotted line). (c) OS from first randomization by in vitro sensitivity to the randomized treatment (sensitive=solid line, intermediate=hashed line, resistant=hashed/dotted line).
See this image and copyright information in PMC

References

    1. Bosanquet AG, Burlton AR, Bell PB, Harris AL. Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP. Br J Cancer. 1997;76:511–518. - PMC - PubMed
    1. Bosanquet AG, Johnson SA, Richards SM. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br J Haematol. 1999;106:71–77. - PubMed
    1. Bosanquet AG, Richards SM, Wade R, Else M, Matutes E, Dyer MJS, et al. Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. Br J Haematol. 2009;146:384–395. - PubMed
    1. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Bezares RF, on behalf of the UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group and NCRI Chronic Lymphocytic Leukaemia Working Group et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230–239. - PubMed
    1. Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, et al. for the UK National Cancer Research Institute (NCRI) Chronic Lymphocytic Leukaemia Working Group. Biological risk factors identify 3 risk groups in the LRF CLL4 trial independent of treatment allocation. Hematologica. 2010;95:1705–1712. - PMC - PubMed

Publication types

MeSH terms